Exploring Cardano: Inner Workings and Advantages of this Cryptocurrency
Seville.- Economy.- Innova.- STSA inaugurates its new painting and sealing hangar in San Pablo, for 18 million
Innova.- More than 300 volunteers join the Andalucía Compromiso Digital network in one month to facilitate access to ICT
Innova.-AMP.- Ayesa acquires 51% of Sadiel, which will create new technological engineering products and expand markets
A Commission created by the CSD will supervise the RFEF
The AN judge prosecutes the former ETA leader for her responsibility in the kidnapping and murder of Miguel Ángel Blanco
The European Parliament condemns the contacts of the Catalan independence movement with Russia and demands an investigation
The PSC would win the Catalan elections with 39-40 seats, Junts would obtain 28-30 and ERC 27-28, according to the CIS
How Blockchain in being used to shape the future
Not just BTC and ETH: Here Are Some More Interesting Coins Worth Focusing on
Retrópolis brings the golden age of video games and computing to the UPV
Looking for video games that value the neighborhoods of Valencia
UPV researchers improve the efficiency of air conditioning systems using a geothermal heat pump
València is committed to citiverse and smart tourism to be "the reference technological hub of the Mediterranean"
A million people demonstrate in France against Macron's pension reform
Russia launches several missiles against "critical infrastructure" in the city of Zaporizhia
A "procession" remembers the dead of the Calabria shipwreck as bodies continue to wash up on the shore
Prison sentences handed down for three prominent Hong Kong pro-democracy activists
ETH continues to leave trading platforms, Ethereum balance on exchanges lowest in 3 years
Investors invest $450 million in Consensys, Ethereum incubator now valued at $7 billion
Alchemy Integrates Ethereum L2 Product Starknet to Enhance Web3 Scalability at a Price 100x Lower Than L1 Fees
Mining Report: Bitcoin's Electricity Consumption Declines by 25% in Q1 2022
Oil-to-Bitcoin Mining Firm Crusoe Energy Systems Raised $505 Million
Microbt reveals the latest Bitcoin mining rigs -- Machines produce up to 126 TH/s with custom 5nm chip design
Bitcoin's Mining Difficulty Hits a Lifetime High, With More Than 90% of BTC Supply Issued
The Biggest Movers are Near, EOS, and RUNE during Friday's Selloff
Global Markets Spooked by a Hawkish Fed and Covid, Stocks and Crypto Gain After Musk Buys Twitter
Bitso to offset carbon emissions from the Trading Platform's ERC20, ETH, and BTC Transactions
Draftkings Announces 2022 College Hoops NFT Selection for March Madness
At the current price of Regeneron, such an operation would be about $ 13 billion to Sanofi.
The giant French pharmaceutical Sanofi has announced this Monday to get rid of the bulk of its share in the biotech Regeneron, its american partner, valued at approximately $ 13 billion. "Sanofi announced today its intention to sell its stake in the capital of Regeneron", which represents a little more than 20% of american society, said the French group in a press release, stating that their collaboration is ongoing and will continue normally.
READ ALSO >> "Scandal Sanofi" : when the reflexes pavloviens policies face the facts
Regeneron is the american partner of Sanofi, with which it has developed multiple treatments in recent years. Their alliance also has a presence of French in the capital of the us. It must now come to an end, at least for the most part. Of the 23.2 million shares that it holds, Sanofi expects to retain only 400 000. At the current price of Regeneron, such an operation would be about $ 13 billion to Sanofi.
Your support is essential. Subscribe for $ 1 support UsAbout 8 billion shares available on the market
of this amount, 5 billion is reserved for Regeneron, will conduct a repurchase of its own shares. The rest will be put back on the market. Sanofi will soon file papers with the SEC, the gendarme of the us markets. "The collaboration between Sanofi and Regeneron has been one of the most productive in the pharmaceutical sector", stated in the press release Paul Hudson, chief executive officer of Sanofi.
READ ALSO >> Nicolas Bouzou : "The French feel of this case Sanofi as a humiliation,"
"It has allowed us to create value for our two companies, and, especially, to develop five drugs of major importance to patients," he continued. The two companies have developed jointly the Dupixent has already been launched in over thirty countries for several pathologies, including asthma and eczema. "Sanofi is committed to continuing its collaboration with Regeneron, which still fits fully into our overall strategy," noted Paul Hudson.
Read our complete file
Sanofi
André Loesekrug-Pietri : "The CEO of Sanofi is right on the lack of european response" Vaccine against the Covid-19 : what is known of the controversy over the Sanofi group action against Sanofi : health Insurance is moved to the side of 115 million eurosEven if Sanofi, who had referred to the end of 2019 the possibility of selling its stake in Regeneron, does not detail the capital gain potential, it promises to be considerable. This very secondarily since 2004 in the capital of the u.s., the French waited for 2007 to take the bulk of its stake, at a time when the share price of Regeneron was 20 times less than today.
